Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Increases By 21.1%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLIGet Free Report) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totalling 3,220,000 shares, an increase of 21.1% from the August 15th total of 2,660,000 shares. Currently, 9.2% of the company’s stock are short sold. Based on an average trading volume of 239,500 shares, the days-to-cover ratio is presently 13.4 days.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

Several hedge funds have recently added to or reduced their stakes in BCLI. AIGH Capital Management LLC purchased a new position in shares of Brainstorm Cell Therapeutics in the 1st quarter valued at $4,815,000. Renaissance Technologies LLC purchased a new position in shares of Brainstorm Cell Therapeutics during the second quarter worth about $426,000. Liberty Wealth Management LLC acquired a new stake in shares of Brainstorm Cell Therapeutics during the first quarter worth about $496,000. Marshall Wace LLP purchased a new stake in shares of Brainstorm Cell Therapeutics in the 2nd quarter valued at about $139,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Brainstorm Cell Therapeutics by 27.5% in the 1st quarter. JPMorgan Chase & Co. now owns 246,202 shares of the biotechnology company’s stock valued at $827,000 after purchasing an additional 53,036 shares during the period. 20.97% of the stock is currently owned by hedge funds and other institutional investors.

Brainstorm Cell Therapeutics Price Performance

NASDAQ:BCLI opened at $0.96 on Friday. Brainstorm Cell Therapeutics has a 12 month low of $0.95 and a 12 month high of $4.56. The firm has a market capitalization of $43.41 million, a PE ratio of -1.30 and a beta of -0.51. The business’s fifty day moving average price is $1.63 and its 200 day moving average price is $2.20.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Free Report) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.12). As a group, equities analysts anticipate that Brainstorm Cell Therapeutics will post -0.7 EPS for the current year.

Wall Street Analyst Weigh In

Separately, began coverage on shares of Brainstorm Cell Therapeutics in a report on Thursday, August 17th. They set a “hold” rating for the company.

Check Out Our Latest Analysis on Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Company Profile

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Featured Stories

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with's FREE daily email newsletter.